Assistant Professor, Departments of Medicine, and Pathology and Cell Biology
Center for Cancer Systems Therapeutics
Identifying High-Risk Factors of Pancreatic Cancer
Armed with a new two-year, $1 million grant from the Pancreatic Cancer Collective, a global team of researchers, led by Dr. Raul Rabadan, is working to develop a comprehensive computational framework that will identify high-risk factors for pancreatic cancer. The team will attack pancreatic cancer research from multiple disciplines—genomics, mathematics and medicine—to provide an integrated approach to studying the contributing factors to this lethal disease. The need for a deeper understanding of pancreatic cancer is pressing--it is projected to become the second leading cause of cancer-related mortality within the next decade.
Novel Precision Medicine Trial for Metastatic Pancreatic Cancer
Herbert Irving Comprehensive Cancer Center and Systems Biology have been awarded a three-year grant from the Lustgarten Foundation to test a new precision medicine approach aimed at metastatic pancreatic cancer.